- Home
- ASR vs LEGN Comparison
ASR vs LEGN Comparison
Compare ASR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASR
- LEGN
- Stock Information
- Founded
- ASR 1996
- LEGN 2014
- Country
- ASR Mexico
- LEGN United States
- Employees
- ASR N/A
- LEGN N/A
- Industry
- ASR Aerospace
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ASR Consumer Discretionary
- LEGN Health Care
- Exchange
- ASR Nasdaq
- LEGN Nasdaq
- Market Cap
- ASR 10.4B
- LEGN 5.4B
- IPO Year
- ASR 2000
- LEGN 2020
- Fundamental
- Price
- ASR $321.40
- LEGN $28.95
- Analyst Decision
- ASR Hold
- LEGN Strong Buy
- Analyst Count
- ASR 1
- LEGN 12
- Target Price
- ASR $310.00
- LEGN $77.09
- AVG Volume (30 Days)
- ASR 61.2K
- LEGN 1.9M
- Earning Date
- ASR 07-22-2025
- LEGN 05-13-2025
- Dividend Yield
- ASR 7.63%
- LEGN N/A
- EPS Growth
- ASR 29.82
- LEGN N/A
- EPS
- ASR 2.28
- LEGN N/A
- Revenue
- ASR $1,599,173,877.00
- LEGN $728,303,000.00
- Revenue This Year
- ASR $17.15
- LEGN $64.21
- Revenue Next Year
- ASR $9.16
- LEGN $53.69
- P/E Ratio
- ASR $14.07
- LEGN N/A
- Revenue Growth
- ASR 21.93
- LEGN 112.46
- 52 Week Low
- ASR $248.88
- LEGN $27.34
- 52 Week High
- ASR $360.00
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- ASR 45.31
- LEGN 41.56
- Support Level
- ASR $317.34
- LEGN $28.13
- Resistance Level
- ASR $360.00
- LEGN $29.31
- Average True Range (ATR)
- ASR 8.25
- LEGN 1.63
- MACD
- ASR -4.58
- LEGN 0.03
- Stochastic Oscillator
- ASR 12.48
- LEGN 27.01
About ASR Grupo Aeroportuario del Sureste S.A. de C.V.
Grupo Aeroportuario del Sureste SAB de CV and its subsidiaries hold concessions to operate, maintain, and develop airports in the southeast region of Mexico. As an operator of airports, it charges airlines, passengers, and other users fees for using the airports' facilities. The group also derives rental and other income from commercial activities conducted at its airports, such as the leasing of space to restaurants and retailers. The group's operating segments are Cancun, which generates maximum revenue, Aerostar, Airplan, Merida, Villahermosa, Holding and Services, and Others.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.